home / stock / pfe / pfe articles

PFE Articles, Pfizer Inc. - From 12/13/23

Stock Information
Company Name: Pfizer Inc.
Stock Symbol: PFE
Market: NYSE
Website: pfizer.com
Menu
PFE PFE Quote PFE Short PFE News PFE Articles PFE Message Board
Get PFE Alerts

News, Short Squeeze, Breakout and More Instantly...
Why Despegar.com Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session | Benzinga

Shares of Despegar.com, Corp. (NYSE: DESP) rose sharply during Wednesday’s session after the company raised its FY23 financial guidance. The ...
What's Going On With BioNTech (BNTX) Shares? | Benzinga

BioNTech SE - ADR (NASDAQ: BNTX) shares are trading lower by 5.6% to $93.10 Wednesday afternoon. Shares of several COVID vaccine stocks are trading...

Pfizer Issues FY24 Forecast, Joins Target Hospitality, Southwest Airlines And Other Big Stocks Moving Lower On Wednesday | Benzinga

U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 40 points on Wednesday. Shares of Pfizer Inc. (NYSE: PFE) shares fell sh...

Pfizer's Dividend Yield Is 5.7%, Plus Humana And Shake Shack On CNBC's 'Final Trades' | Benzinga

On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Shake Shack Inc (NYSE: SHAK) as his f...
Why Is US Pharma Giant Pfizer Stock Trading Lower Today? | Benzinga

Pfizer Inc (NYSE: PFE) provided its full-year 2024 guidance, which includes the expected financial impact from the Seagen Inc (NASDA...

What's Going On With Moderna Stock Today? | Benzinga

Moderna Inc (NASDAQ: MRNA) announced changes to its operating model to bring focus to its short- and long-term business goals. The compan...

Pfizer Clears Required Regulatory Hurdles To Complete $43B Seagen Acquisition | Benzinga

Pfizer Inc (NYSE: PFE) agreed to donate the rights of royalties from sales of cancer drug Bavencio (avelumab) to the American Associ...
Bristol Myers Squibb Further Diversifies Oncology Portfolio With Mega $8.4B Deal | Benzinga

SystImmune and Bristol Myers Squibb & Co (NYSE: BMY) announced an exclusive license and collaboration agreement for Sy...

Neurology Focused Pasithea Therapeutics Stock Soars Over 150% Today - Here's Why | Benzinga

Pasithea Therapeutics Corp (NASDAQ: KTTA) announced preclinical results from two in vivo studies evaluating the antitumor efficacy o...

Vaccine Player Vaxcyte Can Potentially Disrupt Pfizer's 20-Plus-Year Near Monopoly, Says Analyst | Benzinga

Mizuho Securities initiated coverage on Vaxcyte Inc (NASDAQ: PCVX), a vaccine company targeting bacterial infectious diseases (prima...
Previous 10 Next 10